Cargando…

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis

Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-relate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coimbra, Susana, Figueiredo, Américo, Santos-Silva, Alice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112723/ https://www.ncbi.nlm.nih.gov/pubmed/25093016 http://dx.doi.org/10.2147/CE.S33940

Ejemplares similares

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
por: Feldman, Steven R., et al.
Publicado: (2018)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2023)

Protocol for the safety of brodalumab regarding psychiatric comorbidities in patients with psoriasis
por: Pikou, O., et al.
Publicado: (2022)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
por: Seo, Seong Jun, et al.
Publicado: (2020)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
por: Elgaard, Cathrine Dawn Büttner, et al.
Publicado: (2023)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Severe Psoriasis Successfully Treated with Brodalumab after Eradication of Hepatitis C Virus with Glecaprevir and Pibrentasvir: A Case Report
por: Ito, Michiko, et al.
Publicado: (2021)

Brodalumab in the treatment of psoriatic arthritis – the latest reports
por: Banaszczyk, Katarzyna
Publicado: (2021)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study
por: Ohata, Chika, et al.
Publicado: (2023)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
por: Gordon, KB, et al.
Publicado: (2014)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
por: Di Lernia, V, et al.
Publicado: (2016)

Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
por: Kokolakis, Georgios, et al.
Publicado: (2021)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Rapid resolution of pyoderma gangrenosum with brodalumab therapy
por: Tee, Michael W., et al.
Publicado: (2020)

Two-Year US Pharmacovigilance Report on Brodalumab
por: Lebwohl, Mark, et al.
Publicado: (2020)

Three‐year U.S. pharmacovigilance report of brodalumab
por: Lebwohl, Mark, et al.
Publicado: (2021)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

A Case of Psoriasis Vulgaris Treated with Brodalumab in a Hemodialysis Patient with End-Stage Renal Disease due to Diabetic Nephropathy
por: Ishibashi, Masafumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bm4hvekpdetipsipugtkoq266t